Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Common Equity: 2020-2025

Historic Common Equity for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $160.0 million.

  • Tango Therapeutics' Common Equity fell 30.17% to $160.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year decrease of 30.17%. This contributed to the annual value of $199.5 million for FY2024, which is 21.17% down from last year.
  • Latest data reveals that Tango Therapeutics reported Common Equity of $160.0 million as of Q3 2025, which was up 18.58% from $135.0 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Common Equity high stood at $365.4 million for Q3 2021, and its period low was $5.0 million during Q1 2021.
  • Its 3-year average for Common Equity is $215.7 million, with a median of $227.3 million in 2023.
  • As far as peak fluctuations go, Tango Therapeutics' Common Equity skyrocketed by 20,284.90% in 2021, and later slumped by 45.51% in 2025.
  • Over the past 5 years, Tango Therapeutics' Common Equity (Quarterly) stood at $344.7 million in 2021, then fell by 27.64% to $249.5 million in 2022, then rose by 1.46% to $253.1 million in 2023, then dropped by 21.17% to $199.5 million in 2024, then slumped by 30.17% to $160.0 million in 2025.
  • Its Common Equity stands at $160.0 million for Q3 2025, versus $135.0 million for Q2 2025 and $166.8 million for Q1 2025.